192 related articles for article (PubMed ID: 33539574)
1. Formulation of a recombinant HIV-1 polytope candidate vaccine with naloxone/alum mixture: induction of multi-cytokine responses with a higher regulatory mechanism.
Fathi M; Nezamzadeh R; Abdollahpour-Alitappeh M; Yazdi MH; Khoramabadi N; Mahdavi M
APMIS; 2021 Aug; 129(8):480-488. PubMed ID: 33539574
[TBL] [Abstract][Full Text] [Related]
2. Naloxone/alum mixture a potent adjuvant for HIV-1 vaccine: induction of cellular and poly-isotypic humoral immune responses.
Velashjerdi Farahani S; Reza Aghasadeghi M; Memarnejadian A; Faezi S; Shahosseini Z; Mahdavi M
Pathog Glob Health; 2016 Mar; 110(2):39-47. PubMed ID: 26403975
[TBL] [Abstract][Full Text] [Related]
3. A Survey on the Adjuvant Role of Naloxone Alone or Combined with Alum in Vaccination Against Fasciolosis in BALB/c Mice.
Azizi H; Mirzaeei H; Bagheri A; Bazi A; Khamesipour A; Yaghoobi H; Mirzapour A; Khatami M; Elikaee S
Acta Parasitol; 2019 Jun; 64(2):236-245. PubMed ID: 30788648
[TBL] [Abstract][Full Text] [Related]
4. Naloxone and alum synergistically augment adjuvant activities of each other in a mouse vaccine model of Salmonella typhimurium infection.
Jazani NH; Parsania S; Sohrabpour M; Mazloomi E; Karimzad M; Shahabi S
Immunobiology; 2011 Jun; 216(6):744-51. PubMed ID: 21093956
[TBL] [Abstract][Full Text] [Related]
5. Montanide ISA-720 and Naloxone in HBsAg Vaccine Formulation: Cytokine Profiling and Monitoring of Long-Lasting Humoral Immune Responses.
Mirzaee M; Haghighat S; Golkaran B; Asgarhalvaei F; Mirzaee R; Taghizadeh M; Savoji MA; Esfandiari B; Mahdavi M
Biomed Environ Sci; 2022 Sep; 35(9):792-803. PubMed ID: 36189994
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of human papilloma vaccine candidate using naloxone/alum mixture as an adjuvant: increasing immunogenicity of HPV-16E7d vaccine.
Yasaghi M; Mahdavi M
Iran J Basic Med Sci; 2016 Sep; 19(9):1003-1009. PubMed ID: 27803788
[TBL] [Abstract][Full Text] [Related]
7. Mixture of Alum--Naloxone and Alum--Naltrexone as a novel adjuvant elicits immune responses for Toxoplasma gondii lysate antigen in BALB /c mice.
Khorshidvand Z; Shahabi S; Mohamadzade H; Daryani A; Hazrati Tappeh K
Exp Parasitol; 2016 Mar; 162():28-34. PubMed ID: 26773164
[TBL] [Abstract][Full Text] [Related]
8. Immune responses to HIV-1 polytope vaccine candidate formulated in aqueous and alcoholic extracts of Propolis: Comparable immune responses to Alum and Freund adjuvants.
Mojarab S; Shahbazzadeh D; Moghbeli M; Eshraghi Y; Bagheri KP; Rahimi R; Savoji MA; Mahdavi M
Microb Pathog; 2020 Mar; 140():103932. PubMed ID: 31857237
[TBL] [Abstract][Full Text] [Related]
9. Improvement of the inactivated SARS-CoV-2 vaccine potency through formulation in alum/naloxone adjuvant; Robust T cell and anti-RBD IgG responses.
Haghighi M; Khorasani A; Karimi P; Mahdavi M
Iran J Basic Med Sci; 2022 May; 25(5):554-561. PubMed ID: 35911642
[TBL] [Abstract][Full Text] [Related]
10. Induction of protective immunity against brucellosis in mice by vaccination with a combination of naloxone, alum, and heat-killed Brucella melitensis 16 M.
Motaharinia Y; Rezaee MA; Rashidi A; Jalili A; Rezaie MJ; Shapouri R; Hossieni W; Rahmani MR
J Microbiol Immunol Infect; 2013 Aug; 46(4):253-8. PubMed ID: 22727892
[TBL] [Abstract][Full Text] [Related]
11. Pseudomonas aeruginosa flagellin as an adjuvant: superiority of a conjugated form of flagellin versus a mixture with a human immunodeficiency virus type 1 vaccine candidate in the induction of immune responses.
Delavari S; Sohrabi M; Ardestani MS; Faezi S; Tebianian M; Taghizadeh M; Shajiei A; Hosseini SY; Moghaddampour M; Mahdavi M
J Med Microbiol; 2015 Nov; 64(11):1361-1368. PubMed ID: 26404477
[TBL] [Abstract][Full Text] [Related]
12. Protective effect of pilin protein with alum+naloxone adjuvant against acute pulmonary Pseudomonas aeruginosa infection.
Banadkoki AZ; Keshavarzmehr M; Afshar Z; Aleyasin N; Fatemi MJ; Behrouz B; Hashemi FB
Biologicals; 2016 Sep; 44(5):367-73. PubMed ID: 27427517
[TBL] [Abstract][Full Text] [Related]
13. Different Formulations of Inactivated SARS-CoV-2 Vaccine Candidates in Human Compatible Adjuvants: Potency Studies in Mice Showed Different Platforms of Immune Responses.
Haghighi M; Khorasani A; Karimi P; Keshavarz R; Mahdavi M
Viral Immunol; 2022 Dec; 35(10):663-672. PubMed ID: 36534465
[TBL] [Abstract][Full Text] [Related]
14. Naltrexone; as an efficient adjuvant in induction of Th1 immunity and protection against Fasciola hepatica infection.
Azizi H; Mirzaeei H; Nasiri AA; Bazi A; Mirzapour A; Khatami M; Nahavandi KH; Azimi A; Yaghoobi H
Exp Parasitol; 2018 Jun; 189():66-71. PubMed ID: 29729492
[TBL] [Abstract][Full Text] [Related]
15. The new nano-complex, Hep-c, improves the immunogenicity of the hepatitis B vaccine.
Fakharzadeh S; Kalanaky S; Hafizi M; Goya MM; Masoumi Z; Namaki S; Shakeri N; Abbasi M; Mahdavi M; Nazaran MH
Vaccine; 2013 May; 31(22):2591-7. PubMed ID: 23583463
[TBL] [Abstract][Full Text] [Related]
16. A novel adjuvant, a mixture of alum and the general opioid antagonist naloxone, elicits both humoral and cellular immune responses for heat-killed Salmonella typhimurium vaccine.
Jazani NH; Sohrabpour M; Mazloomi E; Shahabi S
FEMS Immunol Med Microbiol; 2011 Feb; 61(1):54-62. PubMed ID: 21054579
[TBL] [Abstract][Full Text] [Related]
17. Formulation of HBsAg in Montanide ISA 51VG adjuvant: Immunogenicity study and monitoring long-lived humoral immune responses.
Savoji MA; Sereshgi MMA; Ghahari SMM; Asgarhalvaei F; Mahdavi M
Int Immunopharmacol; 2021 Jul; 96():107599. PubMed ID: 33848910
[TBL] [Abstract][Full Text] [Related]
18. Vaccine adjuvants CpG (oligodeoxynucleotides ODNs), MPL (3-O-deacylated monophosphoryl lipid A) and naloxone-enhanced Th1 immune response to the Plasmodium vivax recombinant thrombospondin-related adhesive protein (TRAP) in mice.
Nazeri S; Zakeri S; Mehrizi AA; Djadid ND; Snounou G; Andolina C; Nosten F
Med Microbiol Immunol; 2018 Nov; 207(5-6):271-286. PubMed ID: 29948091
[TBL] [Abstract][Full Text] [Related]
19. Granulocyte-macrophage colony-stimulating factor, a potent adjuvant for polarization to Th-17 pattern: an experience on HIV-1 vaccine model.
Mahdavi M; Tajik AH; Ebtekar M; Rahimi R; Adibzadeh MM; Moozarmpour HR; Beikverdi MS; Olfat S; Hassan ZM; Choopani M; Kameli M; Hartoonian C
APMIS; 2017 Jun; 125(6):596-603. PubMed ID: 28493367
[TBL] [Abstract][Full Text] [Related]
20. Comparison of AS03 and Alum on immune responses elicited by A/H3N2 split influenza vaccine in young, mature and aged BALB/c mice.
Yam KK; Gupta J; Allen EK; Burt KR; Beaulieu É; Mallett CP; Burt DS; Ward BJ
Vaccine; 2016 Mar; 34(12):1444-51. PubMed ID: 26873056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
